Trials / Completed
CompletedNCT00044382
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-30
- First posted
- 2002-08-29
- Last updated
- 2019-11-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00044382. Inclusion in this directory is not an endorsement.